Palifermin
Mucocutaneous Epithelial Cell Growth Factor — VARIOUS
Also known as: 24-163 fibroblast growth factor 7 (human), 24-163-Keratinocyte growth factor (human), kepivance, QMS40680K6
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Palifermin is a drug in the Mucocutaneous Epithelial Cell Growth Factor class catalogued in DrugCentral. It was first approved by the FDA in 2004. DrugCentral lists 1 molecular target, including FGFR2. Recorded indications include Drug-induced mucositis, Mucositis following radiation therapy and Prevention of Radiation Therapy-Induced Mucositis.
- Drug class: Mucocutaneous Epithelial Cell Growth Factor.
- Molecular targets: FGFR2 (1 listed in DrugCentral).
- Indications: Drug-induced mucositis, Mucositis following radiation therapy and Prevention of Radiation Therapy-Induced Mucositis.
- ATC code: V03AF08 (Detoxifying agents for antineoplastic treatment).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Drug-induced mucositis
- Mucositis following radiation therapy
- Prevention of Radiation Therapy-Induced Mucositis
Mechanism & targets
| Established pharmacologic class | Mucocutaneous Epithelial Cell Growth Factor |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Fibroblast growth factor receptor 2 | FGFR2 | agonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2004-12-15 | FDA | — | BIOVITRUM AB |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V03AF08 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Mucosal inflammation | 116.1 |
| Febrile neutropenia | 62.2 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Palifermin used for?
DrugCentral lists the following indications for Palifermin: Drug-induced mucositis, Mucositis following radiation therapy and Prevention of Radiation Therapy-Induced Mucositis.
How does Palifermin work?
Its molecular targets in DrugCentral include FGFR2 (agonist).
When was Palifermin first approved?
Palifermin was first approved by the FDA in 2004.
What drug class does Palifermin belong to?
Palifermin is in the Mucocutaneous Epithelial Cell Growth Factor class.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4804 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201821 — compound record and bioactivity
- DrugBank DB00039 — drug record
- FDA UNII QMS40680K6 — substance identity
- DailyMed: FDA labels for Palifermin — current prescribing information (label search)
- UniProt P21802 (FGFR2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.